Cytochrome P450 2D6 genotype and methadone steady-state concentrations

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology

Background:

• Cytochrome P450 2D6 (CYP2D6) exhibits genetic polymorphism, leading to distinct metabolic phenotypes: poor, extensive, and ultrarapid metabolizers.
• Methadone maintenance treatment (MMT) is a cornerstone therapy for opioid dependence, with its efficacy influenced by individual drug metabolism.

Purpose of the Study:

• To investigate the relationship between CYP2D6 genotypes and steady-state plasma concentrations of methadone enantiomers.
• To assess the impact of CYP2D6 metabolic status on MMT outcomes, including illicit opiate use and withdrawal symptoms.

Main Methods:

• Plasma levels of (R)-, (S)-, and (R,S)-methadone were measured in 256 MMT patients.
• Patients were genotyped for CYP2D6 to determine their metabolic status (poor, extensive, or ultrarapid).
• Medical records were reviewed to evaluate MMT success based on treatment adherence and symptom absence.

Main Results:

• Significant differences in (R)-, (S)-, and (R,S)-methadone concentrations relative to dose-to-weight ratios were observed across CYP2D6 genotypes (p < 0.05).
• (R)-methadone levels were significantly lower in ultrarapid metabolizers compared to poor metabolizers (p = 0.009).
• While not statistically significant (p = 0.103), a higher proportion of poor metabolizers (72%) achieved successful treatment outcomes compared to ultrarapid metabolizers (40%).

Conclusions:

• CYP2D6 plays a significant role in the metabolism of methadone.
• CYP2D6 ultrarapid metabolizer status may influence methadone pharmacokinetics, warranting further investigation into its impact on MMT efficacy.